The original product, WHODrug Dictionary, was first created to support the needs of UMC worldwide pharmacovigilance activities. Since then, the product has evolved and grown to become an essential global standard, known today as WHODrug Enhanced. From 2017, WHODrug Enhanced will also include all the records which were previously found in WHODrug Herbal.
With its unique hierarchical drug-code system and extensive coverage, WHODrug Enhanced meets the standards of a consistent drug dictionary with exact terminology. As the reference resource for drugs from across the world, it helps users to identify product names, their active ingredients, and therapeutic uses by the Anatomical Therapeutic Chemical (ATC) classification system.
WHODrug Enhanced contains conventional medicines and herbal remedies. WHODrug conventional medicines records include prescription-only products, over-the-counter (OTC) and pharmacist-dispensed preparations, as well as biotech and blood products, diagnostic substances and contrast media. Products and substances registered by the U.S Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are also routinely recorded.
Regulators around the world, such as the US Food and Drug Administration (FDA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), recommend using WHODrug Enhanced. By doing so, regulators emphasise the importance of submitting drug data in a standardised form, and the value of using a common dictionary and exact terminology across clinical trials and throughout the monitoring of medicine safety.
WHODrug Enhanced is an indispensable source when interpreting and evaluating drug safety issues in Vigibase, the WHO Global Individual Case Safety Report (ICSR) database of suspected adverse drug reactions (ADRs). The use of WHODrug Enhanced facilitates identification and data aggregation at different levels of precision to ensure effective and accurate signal analysis.
For more information please contact us at WHODrug@who-umc.org.